In last trading session, 2seventy bio Inc (NASDAQ:TSVT) saw 0.31 million shares changing hands with its beta currently measuring 1.75. Company’s recent per share price level of $2.61 trading at -$0.07 or -2.61% at ring of the bell on the day assigns it a market valuation of $134.65M. That closing price of TSVT’s stock is at a discount of -129.89% from its 52-week high price of $6.00 and is indicating a premium of 12.26% from its 52-week low price of $2.29.
For 2seventy bio Inc (TSVT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.60. Splitting up the data highlights that, out of 7 analysts covering the stock, 1 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 5 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.08 in the current quarter.
2seventy bio Inc (NASDAQ:TSVT) trade information
Upright in the red during last session for losing -2.61%, in the last five days TSVT remained trading in the green while hitting it’s week-highest on Thursday, 02/20/25 when the stock touched $2.61 price level, adding 7.45% to its value on the day. 2seventy bio Inc’s shares saw a change of -11.22% in year-to-date performance and have moved 2.35% in past 5-day. 2seventy bio Inc (NASDAQ:TSVT) showed a performance of 3.57% in past 30-days.
Wall Street analysts have assigned a consensus price target of 2 to the stock, which implies a fall of -30.5% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 2. It follows that stock’s current price would jump 23.37% in reaching the projected high whereas dropping to the targeted low would mean a gain of 23.37% for stock’s current value.
2seventy bio Inc (TSVT) estimates and forecasts
This year revenue growth is estimated to fall -49.81% from the last financial year’s standing.
4 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 12.83M for the same. And 4 analysts are in estimates of company making revenue of 13.87M in the next quarter. Company posted 10.68M and 12.44M of sales in current and next quarters respectively a year earlier.
In 2025, company’s earnings growth rate is likely to be around 81.00% while estimates for its earnings growth in next 5 years are of 83.03%.
2seventy bio Inc (NASDAQ:TSVT)’s Major holders
KYNAM CAPITAL MANAGEMENT, LP is the top institutional holder at TSVT for having 5.95 million shares of worth $22.92 million. And as of 2024-06-30, it was holding 11.4089 of the company’s outstanding shares.
The second largest institutional holder is GOLDMAN SACHS GROUP INC, which was holding about 4.14 million shares on 2024-06-30. The number of shares represents firm’s hold over 7.9465 of outstanding shares, having a total worth of $15.93 million.
On the other hand, Vanguard Total Stock Market Index Fund and iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Sep 30, 2024 , the former fund manager was holding 1.54 shares of worth $4.03 million or 2.99% of the total outstanding shares. The later fund manager was in possession of 1.4 shares on Nov 30, 2024 , making its stake of worth around $3.66 million in the company or a holder of 2.72% of company’s stock.
